Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Elevating our therapeutic expectations in overactive bladder.

¹Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine Evanston, Illinois, USA.

Journal of the American Academy of Nurse Practitioners

|November 17, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The female urethra: urethral function throughout a woman's lifetime.

International urogynecology journal·2023

Same author

A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS).

Neurourology and urodynamics·2023

Same author

Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study.

Urology·2021

Same author

Vaginal calculus in a patient with a mid-urethral sling mesh exposure.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2020

Same author

Nocturia: A Highly Prevalent Disorder With Multifaceted Consequences.

Urology·2019

Same author

Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.

The Journal of urology·2019

Same journal

The consensus model for regulation of APRNs: Implications for nurse practitioners.

Journal of the American Academy of Nurse Practitioners·2015

Same journal

Effectiveness of nurse practitioner coordinated team group visits for type 2 diabetes in medically underserved Appalachia.

Journal of the American Academy of Nurse Practitioners·2012

Same journal

Prevalence of postpartum depression among Hispanic immigrant women.

Journal of the American Academy of Nurse Practitioners·2012

Same journal

A description of barriers and facilitators to childhood vaccinations in the military health system.

Journal of the American Academy of Nurse Practitioners·2012

Same journal

Evidence-based practice for the busy nurse practitioner: part three: critical appraisal process.

Journal of the American Academy of Nurse Practitioners·2012

Same journal

Obstructive sleep apnea hypopnea syndrome and metabolic syndrome: a synergistic cardiovascular risk factor.

Journal of the American Academy of Nurse Practitioners·2012

See all related articles

Antimuscarinic drugs treat overactive bladder (OAB) by relaxing bladder muscles. Extended-release formulations and newer agents like darifenacin and solifenacin may offer improved side effect profiles for OAB management.

Area of Science:

Pharmacology
Urology

Background:

Overactive bladder (OAB) is commonly treated with antimuscarinic agents that inhibit acetylcholine receptors.
Major side effects of current antimuscarinics are anticholinergic, including dry mouth and constipation.
Oxybutynin and tolterodine are established OAB treatments available in various formulations.

Purpose of the Study:

To review current drug therapy for overactive bladder (OAB).
To compare the efficacy and adverse effects of existing and emerging antimuscarinic agents for OAB.

Main Methods:

Review of existing literature on antimuscarinic drugs for OAB.
Comparison of adverse effect profiles and efficacy data for various agents.

Main Results:

Related Experiment Videos

Extended-release formulations of oxybutynin and tolterodine show fewer side effects than immediate-release versions with similar efficacy.
Trospium has similar efficacy and dry mouth incidence to existing agents but does not cross the blood-brain barrier.
Newer agents, darifenacin and solifenacin, demonstrate improved efficacy for OAB symptoms, including urgency, with lower rates of dry mouth at effective doses.

Conclusions:

Extended-release formulations and newer antimuscarinic agents represent advancements in OAB treatment.
Emerging drugs like darifenacin and solifenacin show promise for managing OAB with potentially reduced anticholinergic side effects.